Modern metabolic peptide conversations increasingly use dual agonist and triple agonist language. Dual usually means two receptor targets. Triple, in retatrutide sponsor language, adds glucagon-receptor activity to GIP and GLP-1. This article teaches the vocabulary so readers can parse papers and press releases without inventing personal protocols.
Agonist, dual, and triple in plain language
An agonist activates a receptor. Dual agonist language means two receptor systems are intentionally engaged. Triple agonist language means three. Those are design claims that still need evidence and, for medicines, labeling.
How to read multi-agonist claims in papers
Look for receptor assay data, in vivo model limits, and whether the molecule is a tool compound or a clinical candidate. Do not upgrade a pharmacology sentence into a consumer product story.
Approved dual-agonist status detail is in tirzepatide research status. Investigational triple-agonist status is in retatrutide investigational status.
Links back to the Research & Science hub
This vocabulary page sits under peptide research and science. Start from GLP-1 peptide medicines explained if you still need the category map before receptor-count language.
